Athira Pharma’s Alzheimer’s drug fails in mid-to-late stage trial, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Athira Pharma’s Alzheimer’s ***** fails in mid-to-late stage trial, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

London: Athira Pharma said on Tuesday its ***** ******* to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer’s ********.

The experimental *****, fosgonimeton, ******* to reach statistical significance in a test that measures cognition and other functions, compared to placebo at 26 weeks.

“These are not the results we hoped for,”  said Chief Medical Officer Javier Martin.

The lack of clinical decline in the placebo group, combined with the short duration of the study, may have impacted the trial’s ability to translate the effect of fosgonimeton into meaningful benefit, Martin added.

The trial evaluated the efficacy and safety of once-daily injections of fosgonimeton in 312 patients.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)

• Published On Sep 4, 2024 at 07:16 AM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#Athira #Pharmas #Alzheimers #***** #fails #midtolate #stage #trial #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up